Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$132.15

-0.45 (-0.34%)

09:08
07/18/17
07/18
09:08
07/18/17
09:08

Johnson & Johnson says FY17 guidance does not include potential U.S. tax reform

  • 18

    Jul

  • 09

    Aug

JNJ Johnson & Johnson
$132.15

-0.45 (-0.34%)

06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.

TODAY'S FREE FLY STORIES

TYPE

Monotype Imaging

$18.45

-0.35 (-1.86%)

07:03
07/28/17
07/28
07:03
07/28/17
07:03
Earnings
Monotype Imaging sees Q3 adjusted EPS 12c-16c, consensus 16c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

LAD

Lithia Motors

$100.05

-0.08 (-0.08%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Earnings
Lithia Motors reports Q2 adjusted EPS $2.28, consensus $2.22 »

Reports Q2 revenue $2.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CMS

CMS Energy

$46.89

0.36 (0.77%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Earnings
Breaking Earnings news story on CMS Energy »

CMS Energy backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

AAN

Aaron's

$40.62

0.88 (2.21%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Hot Stocks
Aaron's acquires SEI/Aaron's franchisee for $140M »

Aaron's has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

HRC

Hill-Rom

$79.70

-2.88 (-3.49%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Earnings
Hill-Rom sees Q4 adj. EPS $1.26-$1.30, consensus $1.33 »

Sees Q4 revenue up 3%-4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 06

    Aug

  • 10

    Aug

  • 15

    Aug

TYPE

Monotype Imaging

$18.45

-0.35 (-1.86%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Earnings
Monotype Imaging reports Q2 adjusted EPS 8c, consensus 9c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CMS

CMS Energy

$46.89

0.36 (0.77%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Earnings
CMS Energy reports Q2 EPS 33c, consensus 39c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Recommendations
Heritage Commerce analyst commentary  »

Heritage Commerce premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

JPM

JPMorgan

$91.55

-0.38 (-0.41%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
JPMorgan says to be 100% reliant on renewable energy by 2020 »

JPMorgan Chase is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

HRC

Hill-Rom

$79.70

-2.88 (-3.49%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Hill-Rom reports Q3 adj. EPS 91c, consensus 91c »

Reports Q3 revenue $689M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 06

    Aug

  • 10

    Aug

  • 15

    Aug

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax raises FY17 adjusted EPS view to $1.65-$1.75 from $1.60-$1.75 

Consensus $1.73.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax reports Q2 adjusted EPS 43c, consensus 43c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

DVAX

Dynavax

$9.25

-1.15 (-11.06%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
Breaking Hot Stocks news story on Dynavax »

Dynavax trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 31

    Jul

  • 10

    Aug

EA

Electronic Arts

$117.60

-0.4 (-0.34%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

UFS

Domtar

$38.49

0.06 (0.16%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Earnings
Domtar reports Q2 EPS 61c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$11.83

-0.07 (-0.59%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Periodicals
Fiat Chrysler's Maserati to launch electric model after 2019, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$45.16

-0.57 (-1.25%)

06:57
07/28/17
07/28
06:57
07/28/17
06:57
Earnings
Valero Energy Partners reports Q2 EPS 69c, consensus 75c »

Reports Q2 revenue $110M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

ZBH

Zimmer Biomet

$125.44

-3.26 (-2.53%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Zimmer Biomet rating change  »

Zimmer Biomet downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

JCI

Johnson Controls

$40.14

-3.18 (-7.34%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Johnson Controls rating change  »

Johnson Controls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 08

    Aug

X

U.S. Steel

$25.00

-1.2 (-4.58%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
U.S. Steel rating change  »

U.S. Steel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck reports Q2 KEYTRUDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VC

Visteon

$111.53

1.56 (1.42%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
QEP Resources rating change  »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

MRK

Merck

$63.69

1.89 (3.06%)

06:52
07/28/17
07/28
06:52
07/28/17
06:52
Hot Stocks
Merck CEO Q2 results driven by 'robust momentum for KEYTRUDA' »

"We continued to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

PLT

Plantronics

$53.65

0.15 (0.28%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Downgrade
Plantronics rating change  »

Plantronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.